Literature DB >> 16465772

Malignant lymphoma of the central nervous system: difficult histologic diagnosis after glucocorticoid therapy prior to biopsy.

Y L Choi1, Y L Suh, D Kim, Y H Ko, C O Sung, J I Lee.   

Abstract

Four cases of central nervous system (CNS) lymphoma are reported which presented obstacles in diagnosis due to steroid treatment prior to biopsy. Reliable diagnoses were provided by molecular analysis. Malignant lymphoma of the CNS may be indistinguishable from other conditions, even in view of the gravity of the diagnosis. All patients had a previous history of glucocorticoid injection, for 2-18 days prior to stereotactic brain biopsy. The pathologic examination revealed in all cases axonal destruction and reactive gliosis with a variable infiltration of B- or T lymphocytes and macrophages. Characteristically, scattered degenerating small round cells with pyknotic or fragmented nuclei were also observed. However, the molecular assessment of paraffin-embedded tissues revealed the monoclonal IgH gene rearrangement, which allowed the confident diagnosis of B cell lymphoma. The histopathological findings of the present cases suggest that the tumor cells might be selectively destroyed by steroid treatment, which may render diagnosis impossible. Thus, molecular genetic investigation constitutes an important tool for establishing a diagnosis of CNS lymphoma obscured by steroid administration. This is especially true in cases where a paucity of tumor cells is observed or when monoclonality fails to be demonstrated by immunohistochemical tests.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16465772

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  6 in total

1.  Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma: effect of prior corticosteroid therapy.

Authors:  Elena Kan; Itai Levy; Daniel Benharroch
Journal:  Virchows Arch       Date:  2009-09-09       Impact factor: 4.064

2.  Motor deficits at presentation and predictors of overall survival in central nervous system lymphomas.

Authors:  Yu Tung Lo; Ya Lyn Samantha Ang; Valerie Shiwen Yang; Dave Thevandiran Kanavathy; Sai Liang; Lester Lee
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

3.  The Impact of Early Corticosteroid Pretreatment Before Initiation of Chemotherapy in Patients With Primary Central Nervous System Lymphoma.

Authors:  Florian Gessler; Joshua D Bernstock; Bedjan Behmanesh; Uta Brunnberg; Patrick Harter; Daniel Ye; Gregory K Friedman; Martin-Leo Hansmann; Marlies Wagner; Volker Seifert; Lutz Weise; Gerhard Marquardt
Journal:  Neurosurgery       Date:  2019-08-01       Impact factor: 4.654

4.  Glioblastoma presenting with steroid-induced pseudoregression of contrast enhancement on magnetic resonance imaging.

Authors:  Marcus D Mazur; Vinh Nguyen; Daniel W Fults
Journal:  Case Rep Neurol Med       Date:  2012-07-11

5.  Analysis of Cellular Heterogeneity in Immune Microenvironment of Primary Central Nervous System Lymphoma by Single-Cell Sequencing.

Authors:  Boyuan Wei; Zhe Liu; Yue Fan; Shuwei Wang; Chao Dong; Wei Rao; Fan Yang; Gang Cheng; Jianning Zhang
Journal:  Front Oncol       Date:  2021-10-04       Impact factor: 6.244

Review 6.  Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.

Authors:  Tong Chen; Yuanbo Liu; Yang Wang; Qing Chang; Jinsong Wu; Zhiliang Wang; Daoying Geng; Jin-Tai Yu; Yuan Li; Xiao-Qiu Li; Hong Chen; Dongxiao Zhuang; Jianyong Li; Bin Wang; Tao Jiang; Lanting Lyu; Yuqin Song; Xiaoguang Qiu; Wenbin Li; Song Lin; Xinghu Zhang; Dehong Lu; Junqiang Lei; Yaolong Chen; Ying Mao
Journal:  J Hematol Oncol       Date:  2022-09-29       Impact factor: 23.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.